Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series

Braimah, Imoro Zeba; Agyabeng, Kofi; Amoaku, Winfried

doi:10.1007/s10792-021-01799-w

Cited by 3 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti-VEGF drugs have been widely used in ocular diseases such as exudative age-related macular degeneration, diabetic macular edema, choroidal neovascularization, and RVO-ME, and have shown good safety and efficacy. Previous retrospective and prospective studies have shown that the anti-VEGF treatment for RVO-ME in real-word has achieved significant retinal structure improvement and visual function recovery ( 5 , 17 , 29 , 33 , 37 , 38 ). The patients included in this study are divided into the mAb group (ranibizumab injection) and the Fc group (injection of conbercept or aflibercept) according to their mechanism of action.…”

Section: Discussionmentioning

confidence: 99%

“…In other studies, age and disease duration are baseline factors that can affect visual function following anti-VEGF treatment ( 16 , 31 ). The eyes of ME secondary to BRVO are showing a better visual prognosis compared with CRVO ( 32 , 33 ). In this study, younger patients with a shorter disease duration are associated with better visual outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…Further, some studies have demonstrated that in patients with a long duration of disease, the damage to the photoreceptor and other retinal structures is irreversible. Even when ME is completely dissolved, the long-term visual outcome may be poor ( 17 , 33 , 35 ). This is consistent with our research results.…”

Section: Discussionmentioning

confidence: 99%

“…has achieved significant retinal structure improvement and visual function recovery (5,17,29,33,37,38). The patients included in this study are divided into the mAb group (ranibizumab injection) and the Fc group (injection of conbercept or aflibercept) according to their mechanism of action.…”

Section: ) (E)mentioning

confidence: 99%

See 3 more Smart Citations

Two-Week Central Macular Thickness Reduction Rate >37% Predicts the Long-Term Efficacy of Anti-vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Zhou

et al. 2022

Front. Med.

View full text Add to dashboard Cite

ObjectiveTo determine if the early response assessments can predict the long-term efficacy of anti-vascular endothelial growth factor (VEGF) treatment for macular edema secondary to retinal vein occlusion (RVO-ME).MethodsA retrospective study of patients with diagnosis of RVO-ME and intravitreal anti-VEGF treatment was conducted. Clinical characteristics including age, gender, disease subtype and disease duration were recorded at baseline. The best corrected visual acuity (BCVA and logMAR), intraocular pressure (IOP), and central macular thickness (CMT) were recorded at baseline, 2 weeks, and every month (months 1–6) after injection. Further, we compared the early response assessments between the cured group (6-month CMT ≤ 250 μm) and the uncured group (6-month CMT > 250 μm).ResultsA total of 164 eyes in 164 patients (77 male and 87 female) were included. At each post-injection time point, both BCVA and CMT are significantly decreased from baseline (all P < 0.001). Spearman’s test showed that 2-week CMT reduction rate after the first injection was negatively correlated with BCVA at 6 months (r = −0.359, P < 0.001). Compared with the uncured group (47 cases), the cured group (117 cases) was younger (59.53 ± 11.68 vs. 65.19 ± 13.10 years old, P < 0.01), had more BRVO patients (76.1% vs. 44.7%, P < 0.01), a shorter disease duration (1.92 ± 2.43 vs. 5.05 ± 4.32 months, P < 0.01), lower baseline CMT (527.09 ± 154.95 vs. 768.96 ± 287.75 μm, P < 0.01), and lower baseline BCVA (0.86 ± 0.44 vs. 1.31 ± 0.51, P < 0.01). At each post-injection time point, the cured group had lower CMT and BCVA values when compared to the uncured group (all P < 0.01), and the 2-week CMT reduction rate was identified as the earliest response time to predict the long-term treatment efficacy. Moreover, ROC curve analysis indicated that a 2-week CMT reduction rate >37% yielded the best cut-off point for predicting the long-term cure of anti-VEGF treatment at 6 months (P < 0.001). Multivariable logistic regression confirmed that the 2-week CMT reduction rate >37% was independently associated with the 6-month cured rate (OR = 9.639, 95% Cl = 1.030–90.227, P = 0.047).ConclusionAge, disease duration, baseline CMT, and baseline BCVA are associated with visual outcomes at 6-month of anti-VEGF treatment for RVO-ME. The “2-week CMT reduction rate >37%” after the first injection is an independent factor to predict better long-term outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: ) (E)mentioning

confidence: 99%

See 2 more Smart Citations

Two-Week Central Macular Thickness Reduction Rate >37% Predicts the Long-Term Efficacy of Anti-vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Zhou

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…9 Ziv-aflibercept has an identical molecular structure and mechanism of action as aflibercept, which makes it potentially available for ophthalmic use at a much lower cost. Although previous studies have demonstrated that both ziv-aflibercept and bevacizumab appear safe and effective for the treatment of ME secondary to CRVO, [5][6][7][10][11][12][13][14] a prospective comparison between these drugs has never been reported. Therefore, this study aimed to compare the efficacy of intravitreal ziv-aflibercept (IVZ) and intravitreal bevacizumab (IVB) treatment in patients with ME secondary to CRVO over a 6-month period.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial

Sinawat,

Hemanak,

Chanthowong

et al. 2023

OPTH

View full text Add to dashboard Cite

To compare the efficacy of intravitreal ziv-aflibercept (IVZ) and bevacizumab (IVB) injections for the treatment of macular edema secondary to central retinal vein occlusion. Methods: Participants were randomly assigned 1:1 to receive 3 monthly IVZ (1.25 mg/0.05 mL) or IVB (1.25 mg/0.05 mL) followed by the pro-re-nata protocol for persistent or recurrent macular edema. The primary outcomes were best-corrected visual acuity and central subfield thickness. An interim analysis was planned when half of the participants completed the follow-up. Results: Twenty-four participants were recruited. At 6 months, mean best-corrected visual acuity in the IVB and IVZ groups improved from 1.23 ± 0.64 to 0.76 ± 0.56 logMAR (p = 0.003) and from 1.13 ± 0.59 to 0.53 ± 0.26 logMAR (p = 0.003), respectively. The percentage of visual improvement and reduction in central subfield thickness in the IVZ group were insignificantly better than those in the IVB group (44.41 ± 26.72 vs 39.64 ± 24.22%; p = 0.65) and (51.94 ± 20.35 vs 45.78 ± 24.71%; p = 0.51), respectively. Although the mean number of injections was lower in the IVZ group (4.55 ± 1.29 vs 4.82 ±1.33), the difference was not statistically significant (p = 0.68). No ocular or systemic adverse events were observed. Conclusion:The interim analysis demonstrated that the visual and anatomical results of IVZ were insignificantly better than those of IVB at 6 months of follow-up. The results also showed that IVZ was non-inferior to IVB for anatomical improvement but inconclusive for visual improvement. Clinical Trial Registration: (identifier: TCTR20191205008).

show abstract

Cystoid Macular Edema

Mack

Hassall

Hall

et al. 2022

Comprehensive Pharmacology

View full text Add to dashboard Cite

Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series

Cited by 3 publications

References 27 publications

Two-Week Central Macular Thickness Reduction Rate >37% Predicts the Long-Term Efficacy of Anti-vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Two-Week Central Macular Thickness Reduction Rate >37% Predicts the Long-Term Efficacy of Anti-vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial

Cystoid Macular Edema

Contact Info

Product

Resources

About